Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afatinib + ramucirumab
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of afatinib, a second-generation irreversible ErbB family inhibitor, and ramucirumab, a human IgG1 monoclonal antibody targeting VEGFR2. Afatinib covalently binds to and irreversibly blocks signaling from EGFR (ErbB1), HER2 (ErbB2), ErbB3, and HER4 (ErbB4), preventing tyrosine kinase autophosphorylation and downregulating ErbB signaling. Ramucirumab binds to the extracellular domain of VEGFR2, preventing binding of VEGF ligands and inhibiting angiogenesis. This combination has shown efficacy in treating EGFR-mutated non-small cell lung cancer (NSCLC), particularly in patients with uncommon mutations such as L861Q and G719X.
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB4 (Erb-b2 receptor tyrosine kinase 4)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on afatinib + ramucirumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afatinib + ramucirumab.